- Home
- XERS vs IGMS Comparison
XERS vs IGMS Comparison
Compare XERS & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- IGMS
- Stock Information
- Founded
- XERS 2005
- IGMS 1993
- Country
- XERS United States
- IGMS United States
- Employees
- XERS N/A
- IGMS N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- IGMS Health Care
- Exchange
- XERS Nasdaq
- IGMS Nasdaq
- Market Cap
- XERS 500.2M
- IGMS 528.6M
- IPO Year
- XERS 2018
- IGMS 2019
- Fundamental
- Price
- XERS $3.47
- IGMS $6.40
- Analyst Decision
- XERS Buy
- IGMS Buy
- Analyst Count
- XERS 3
- IGMS 7
- Target Price
- XERS $4.87
- IGMS $17.43
- AVG Volume (30 Days)
- XERS 1.8M
- IGMS 211.6K
- Earning Date
- XERS 11-08-2024
- IGMS 11-08-2024
- Dividend Yield
- XERS N/A
- IGMS N/A
- EPS Growth
- XERS N/A
- IGMS N/A
- EPS
- XERS N/A
- IGMS N/A
- Revenue
- XERS $187,361,000.00
- IGMS $2,918,000.00
- Revenue This Year
- XERS $24.27
- IGMS $23.57
- Revenue Next Year
- XERS $18.57
- IGMS $192.36
- P/E Ratio
- XERS N/A
- IGMS N/A
- Revenue Growth
- XERS 22.72
- IGMS 57.64
- 52 Week Low
- XERS $1.69
- IGMS $6.13
- 52 Week High
- XERS $3.87
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- XERS 54.75
- IGMS 27.28
- Support Level
- XERS $3.32
- IGMS $7.00
- Resistance Level
- XERS $3.57
- IGMS $10.80
- Average True Range (ATR)
- XERS 0.18
- IGMS 0.86
- MACD
- XERS -0.01
- IGMS -0.09
- Stochastic Oscillator
- XERS 42.86
- IGMS 5.80
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.